

**III International Scientific and Practical Conference**  
**«HEALTH TECHNOLOGY ASSESSMENT: INNOVATIVE TECHNOLOGIES**  
**IMPLEMENTATION»**

October 3, 2016

Moscow, Russia

The basics of healthcare system performance and quality of medical care enhancement are research, development, implementation and reasonable application of modern innovative technologies.

Implementation of innovative technologies and pharmaceuticals leads to changes in approaches to disease management and in some cases significantly improves outcomes and patients' quality of life. However, technological innovations are often associated with a significant increase in healthcare system costs.

International experience shows wider involvement of not only payers, healthcare experts and economists, but also representatives of industry and the patients themselves in the negotiation process on the financing new technologies. Implementation of innovations in healthcare, unlike that in many other areas is directly related to the healthcare system's ability to make economically viable decisions and the development of the concept of health technology assessment.

In spite of the first steps towards the introduction of comprehensive evaluation of medicines in formulary decision making, development of approaches to financing innovative and expensive technologies is neglected in Russia. So far, despite the limitation of healthcare financial resources such concepts as Risk-Sharing Agreement (RSA) and Multi-Criteria Decision Analysis (MCDA) are still outside the regulatory field. Another approach for financing innovations is a flexible pricing system inclusive value-based assessment of new technologies, as well as within the negotiation process.

Organization for Health Technology Assessment System, taking into account the objectives set out above, would allow to determine the feasibility of the implementation of new, primarily expensive technologies for the social health insurance system based on clinical and economic data.

Implementation of innovations requires not only funding, but also training of physicians, preparation of the system to their application. Investment attractiveness analysis of new health technologies, conducted in the early stages of their establishment, called Early Health Technology Assessment may reduce the development costs thereby increasing innovations' availability to the public.

Based on the foregoing, it was decided to hold in Moscow an international conference «Health Technology Assessment: innovative technologies implementation». The event is supported by the Ministry of Health of the Russian Federation, the Council of the Federation Committee on Social Policy of the Federal Assembly of the Russian Federation, Center of Healthcare Quality Assessment and Control, Financial Research Institute of the Ministry of Finance of the Russian Federation, Autonomous Non-Profit Organization National Center for Health Technology Assessment (ANO NCHTA) and the Skolkovo Foundation.

The event is expected to be attended by representatives of European and BRICS countries' HTA agencies and European network for health technology assessment (EUnetHTA) as well as local and international HTA and drug supply experts.

**Conference members:**

Representatives of federal and regional legislative and executive authorities;  
Heads of relevant regional ministries and agencies of the Russian Federation;  
Representatives of the federal and regional compulsory medical insurance funds;  
Scientific expert community, staff members of Russian Federation medical institutions of higher education;  
Representatives of the Skolkovo Foundation;  
Representatives of the industry and insurance companies;  
Leading specialists of European and BRICS countries' HTA agencies;  
Representatives of the European network for health technology assessment (EUnetHTA);  
Local and international HTA and drug supply experts.

**The conference will focus around the following topics:**

HTA development in Russia;  
Funding of healthcare in Russia;  
Early HTA and its influence on market access;  
Funding of innovative medical technologies;  
Pricing regulation of pharmaceuticals;  
Risk-sharing agreement as a possible model of funding of innovative medical technologies;  
Multi-criteria decision analysis as a tool of measurement of innovativeness of medical technologies.

**Conference venue:**

Renaissance Moscow Monarch Centre Hotel (Andreevsky Hall, second floor), Leningradsky Avenue, 31A/1, Moscow, Russia.

**Start of the registration:** 9:00 am.

**Start of the event:** 10:00 am.

**If you are interested in participation**, please contact us at + 79164797524 or via e-mail [gkh@hta-rus.ru](mailto:gkh@hta-rus.ru).